Top Tweets for #Carsgen
✨#CARsgen 🇨🇳 présente les résultats du suivi à LT de #Zevor_cel 🧬 à l’#IMS25 🇺🇸
Dans l'étude 14 patients atteints d’un #MyélomeMultiple 🩸 R/R
Taux de réponse de 100 % (IC à 95 % : 76,8, 100,0) avec 11 (78,6 %) patients obtenant une réponse complète (RC)
https://t.co/TNi1FNrRkI
🇨🇳 #CARsgen Therapeutics , a company focused on developing innovative CAR T-cell therapies, has announced its 2025 Interim Results. https://t.co/QivPavpoVg
CARsgen’s revenue was around RMB51 million for the six months ended June 30, 2025, mainly from zevor-cel, which was calculated on the basis of ex-works price, rather than end-of-market prices.
Zevorcabtagene autoleucel (zevor-cel, R&D code: CT053) is an autologous fully human CAR T-cell product against B-cell maturation antigen (BCMA) approved by the NMPA of China for the treatment of adult patients with relapsed or refractory multiple myeloma (R/R MM) who have progressed after at least 3 prior lines of therapy (including a proteasome inhibitor and an immunomodulatory agent).
⚡️#CARsgen 🇨🇳 annonce ses résultats intermédiaires pour 2025
Plusieurs produits #CAR_T 🧬 #Allogéniques sont en cours de développement, couvrant des domaines de traitement tels que les hémopathies malignes, les #TumeursSolides et les maladies auto-immunes
https://t.co/Vb2Z7NIkx7
#CARsgen Therapeutics announced that #NDA for its CAR-T therapy, satricabtagene autoleucel (satri-cel, CT041) (an autologous CAR T-cell product candidate against protein Claudin18.2), has been submitted to #China #NMPA's #CDE for the treatment of patients with Claudin18.2-positive advanced gastric/gastroesophageal junction adenocarcinoma (G/GEJA) who have failed at least two prior lines of therapy. https://t.co/ZjWA31edQ4
satri-cel received Breakthrough Therapy Designation from the NMPA’s CDE and priority review for the indication. If approved, satri-cel will become the world’s first commercialized CAR-T cel therapy for solid tumors.
🇨🇳 #CARsgen Therapeutics announces that an abstract of the research results of the confirmatory Ph2 clinical trial of satricabtagene autoleucel (satri-cel, CT041) (an autologous CAR T-cell product candidate against protein Claudin18.2) for advanced G/GEJC in #China (CT041-ST-01, NCT04581473) is available on #ASCO25 . https://t.co/vdXvTKhF6F
mPFS by IRC (3.25m vs 1.77m; HR 0.366, 95% CI: 0.241, 0.557; p<0.0001) and an obvious trend for longer mOS (7.92m vs 5.49m; HR 0.693, 95% CI: 0.457, 1.051; one-sided p=0.0416) than TPC arm.
🇨🇳 #CARsgen Therapeutics announces that the results of CT071 (an autologous CAR T-cell product targeting GPRC5D) for the treatment of newly diagnosed multiple myeloma (NDMM) in an investigator-initiated trial (NCT06407947), were presented in a poster session at #EHA2025 .
The poster was titled “A phase I study of GPRC5D targeting CAR T-cell therapy CT071 for high-risk newly diagnosed multiple myeloma” (Abstract # PF1164). https://t.co/1GNBltxU62
safety: 7 patients (70%) experienced cytokine release syndrome (CRS), all at Grade 1 and resolved. No dose-limiting toxicities (DLTs), immune effector cell-associated neurotoxicity syndrome (ICANS), or death due to treatment-related adverse event (TRAE) occurred.
efficacy: The overall response rate (ORR) was 100%, including stringent complete response (sCR) rate of 70% (7/10). Two (20%) patients achieved very good partial response (VGPR) and one (10%) achieved partial response (PR). Notably, 5 patients achieved sCR by week 4. All 10 patients achieved MRD negativity at 10⁻6 threshold. A robust expansion of CAR-T cells was observed in all patients with a median Cmax of 54,812.0 copies/μg gDNA (range 9,885 to 82,600) and Tmax was 10 days (range 10 to 14).
🇨🇳 #CARsgen Therapeutics announces that an abstract of the research results of the confirmatory Ph2 clinical trial of satricabtagene autoleucel (satri-cel, CT041) (an autologous CAR T-cell product candidate against protein Claudin18.2) for advanced G/GEJC in #China (CT041-ST-01, NCT04581473) is available on #ASCO25 . https://t.co/vdXvTKhF6F
mPFS by IRC (3.25m vs 1.77m; HR 0.366, 95% CI: 0.241, 0.557; p<0.0001) and an obvious trend for longer mOS (7.92m vs 5.49m; HR 0.693, 95% CI: 0.457, 1.051; one-sided p=0.0416) than TPC arm.
🇨🇳 #CARsgen Therapeutics announces preliminary clinical data for #CT0596, an allogeneic BCMA-targeted CAR-T developed using the THANK-u Plus™ platform. https://t.co/toiQbJxSi2
8 R/R MM patients with ≥3L therapy, administer CT0596 following lymphodepletion with the FC regimen (fludarabine 22.5-30 mg/m² and cyclophosphamide 350-500 mg/m²).
4 months follow-up
Key findings:
-No DLTs, ≥Grade 3 CRS, ICANS, or GVHD
-5 patients completed the first efficacy assessment at Week 4:
3 patients (60%) achieved sCR/CR
4 patients (80%) achieved MRD-negativityin the bone marrow.
-Early efficacy data from 2 patients at Day 14
reductions in measurable lesions by ≥92% and ≥65% -1 patient had not yet reached the protocol-specified efficacy assessment timepoint.
-All sCR/CR patients remained in ongoing responses
⚡️#CARsgen 🇨🇳 annonce des données clinique préliminaires pour #CT0596, un #CAR_T 🧬 #Allogénique (#THANKuPlus #CT0596) ciblant #BCMA démontrant une sécurité et une efficacité favorables pour le #MyélomeMultiple 🩸 ou la #Leucémie 🩸 à #Plasmocytoses R/R
https://t.co/PrwMprbYUA
✨#CARsgen 🇨🇳 annonce que le Centre d'évaluation des médicaments (#CDE) de l'Administration nationale des produits médicaux (#NMPA) de #Chine 🇨🇳 a accordé la désignation de "thérapie révolutionnaire" (#BTD) au #Satricabtagene ✂️ autoleucel (« satri-cel », #CT041) pour le traitement du #Cancer avancé de la jonction gastrique/gastro-œsophagienne (G/GEJ) positif à Claudin18.2 chez les patients qui ont échoué à au moins deux lignes de traitement antérieures.
https://t.co/GHJwA5Yl9J
La thérapie #CAR_T ✂️ #Allogénique 🩸 #CD19/#CD20 de #CARsgen 🇨🇳 administre sa première dose chez un patient atteint d'une maladie auto-immune
Le #KJ_C2219 est développé à l’aide de la plate-forme THANK-u Plus™. CARsgen évalue actuellement le traitement dans un IIT en #Chine 🇨🇳 pour les #TumeursMalignes à cellules B et dans un autre IIT pour le #Lupus érythémateux disséminé et la #Sclérose systémique.
https://t.co/zsOkvqOc6c
✨#CARsgen a lancé #Zhuhai SB Xinchuang « #UCARsgen » pour accélérer le développement de produits à base de cellules #CAR_T #Allogéniques en #Chine 🇨🇳, axée sur les thérapies pour le traitement des #Hémopathies malignes.
https://t.co/Tw5uASXWD6
🇨🇳 #CARsgen Announces Positive Topline Results from China GC/GEJ Pivotal Phase II Clinical Trial of Claudin18.2 CAR-T (Satri-cel) https://t.co/gbNoOVZSch
✨#CARsgen 🇨🇳 annonce que son 1er produit #Allogénique à base de cellules #CAR_T ✂️ développé à l'aide de la plateforme #THANK_uPlus, ciblant #BCMA, a administré la 1ère dose à un patient
Le produit est en cours d'évaluation pour le traitement du #MyélomeMultiple 🩸 R/R et de la #Leucémie 🩸 à plasmocytes R/R
https://t.co/hrN4mKOrDU
#Carsgen CT053 US ph2 update of zevor cell seemingly at 1x10e8 fixed dose
n=17 RRMM (median 6 / range 4-17 prior lines) - mFU 113d - 29% EMD - 53% high risk cyto / 11 evaluable with >=8wks of FU
ORR 100%, responses deepeing over time (CR/sCR not mature), all pts w/ MRD assessment
on the back of interesting data for their Claudin6 CAR-T, $BNTX launched a trial w/ a Claudin18.2 CAR-T (BNT141) in Jan. #CARsgen
Safety, PK/PD & Prelim. Efficacy of BNT141 in Unresectable/Met. CLDN18.2+ Gastric, Pancreatic, Ovarian, Biliary Tract Tumors
https://t.co/Kedcp1qKi5
#CARsgen gained 12% to HK$35.20 Wed after dosing 1st subject in its North American Ph 2 LUMMICAR trial of CT053, an autologous BCMA CAR T tx to treat refractory and/or relapsed #MultipleMyeloma. Regulatory submissions expected beginning in 1H22
CARsgen Plans $157M, 200-Job Cancer Cell Therapy Facility in Durham https://t.co/PIQC6J9MPJ @ncbiotech #lifescience #CARsgen #TechTuesday
Read on the CAR-T #therapy market (https://t.co/GOv8tG6oQb)
#WBCs #cancer #immunotherapy #NorthAmerica #COVID19 #coronavirus #pandemic #Novartis #KitePharma #Pfizer #JunoTherapeutics #Celgene #CARsgen #Sorrento #LegendBiotech #TheBusinessResearchCompany #TBRC #GlobalMarketModel
Last Seen Hashtags on Sotwe
كحبه
𝐒𝗘𝗟𝗘𝗖𝗧𝗜𝗩𝗘
Seen from United States
snapchat
Seen from United States
wariaBJ
Seen from Singapore
baqua
Seen from United States
lolorily
Seen from United States
ifşa türk porno
Seen from Turkey
mgai(***************************)*************filter:videos
anxiouspanda()**************************************************************************************************** filter:videos
Seen from Turkey
ankara pasif
Seen from Turkey
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
241.3M followers
Barack Obama
@barackobama
118.8M followers
Cristiano Ronaldo
@cristiano
114.5M followers
Donald J. Trump
@realdonaldtrump
111.9M followers
Narendra Modi
@narendramodi
107M followers
Rihanna
@rihanna
98.7M followers
NASA
@nasa
92.3M followers
Justin Bieber
@justinbieber
91.8M followers
KATY PERRY
@katyperry
90M followers
Taylor Swift
@taylorswift13
84M followers
Lady Gaga
@ladygaga
75.5M followers
Virat Kohli
@imvkohli
73.4M followers
Kim Kardashian
@kimkardashian
70.8M followers
YouTube
@youtube
68.7M followers
Neymar Jr
@neymarjr
66.4M followers
Bill Gates
@billgates
65.2M followers
Selena Gomez
@selenagomez
63.1M followers
The Ellen Show
@theellenshow
62.2M followers
CNN
@cnn
61.7M followers
X
@x
60.6M followers